Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mayne Pharma Group ( (AU:MYX) ) just unveiled an update.
Mayne Pharma Group Limited has announced a court hearing to approve a proposed scheme of arrangement, where Cosette Australia BidCo Pty Ltd will acquire 100% of Mayne Pharma’s shares. This follows the approval of the scheme by Mayne Pharma shareholders in June 2025. The hearing is scheduled for October 22, 2025, at the Supreme Court of New South Wales. Shareholders have the right to appear and oppose the scheme if desired. This acquisition could significantly impact Mayne Pharma’s operations and market positioning, potentially affecting stakeholders involved.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma is an ASX-listed specialty pharmaceutical company that focuses on commercializing novel pharmaceuticals to provide safer and more accessible medicines. It is a leader in dermatology and women’s health in the United States and offers contract development and manufacturing services globally. With a 40-year history, Mayne Pharma has been successful in developing and commercializing new oral drug delivery systems.
Average Trading Volume: 285,011
Technical Sentiment Signal: Buy
Current Market Cap: A$455M
For a thorough assessment of MYX stock, go to TipRanks’ Stock Analysis page.